Cargando…

Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744

BACKGROUND: Eukaryotic translation elongation factor 1A2 (eEF1A2) is a known proto-oncogene. We proposed that stimulation of the eEF1A2 expression in cancer tissues is caused by the loss of miRNA-mediated control. METHODS: Impact of miRNAs on eEF1A2 at the mRNA and protein levels was examined by qPC...

Descripción completa

Detalles Bibliográficos
Autores principales: Vislovukh, A, Kratassiouk, G, Porto, E, Gralievska, N, Beldiman, C, Pinna, G, El'skaya, A, Harel-Bellan, A, Negrutskii, B, Groisman, I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681015/
https://www.ncbi.nlm.nih.gov/pubmed/23695020
http://dx.doi.org/10.1038/bjc.2013.243
_version_ 1782273196027805696
author Vislovukh, A
Kratassiouk, G
Porto, E
Gralievska, N
Beldiman, C
Pinna, G
El'skaya, A
Harel-Bellan, A
Negrutskii, B
Groisman, I
author_facet Vislovukh, A
Kratassiouk, G
Porto, E
Gralievska, N
Beldiman, C
Pinna, G
El'skaya, A
Harel-Bellan, A
Negrutskii, B
Groisman, I
author_sort Vislovukh, A
collection PubMed
description BACKGROUND: Eukaryotic translation elongation factor 1A2 (eEF1A2) is a known proto-oncogene. We proposed that stimulation of the eEF1A2 expression in cancer tissues is caused by the loss of miRNA-mediated control. METHODS: Impact of miRNAs on eEF1A2 at the mRNA and protein levels was examined by qPCR and western blot, respectively. Dual-luciferase assay was applied to examine the influence of miRNAs on 3′-UTR of EEF1A2. To detect miRNA-binding sites, mutations into the 3′-UTR of EEF1A2 mRNA were introduced by the overlap extension PCR. RESULTS: miR-663 and miR-744 inhibited the expression of luciferase gene attached to the 3′-UTR of EEF1A2 up to 20% and 50%, respectively. In MCF7 cells, overexpression of miR-663 and miR-744 reduced the EEF1A2 mRNA level by 30% and 50%. Analogous effects were also observed at the eEF1A2 protein level. In resveratrol-treated MCF7 cells the upregulation of mir-663 and mir-744 was accompanied by downregulation of EEF1A2 mRNA. Both miRNAs were able to inhibit the proliferation of MCF7 cells. CONCLUSION: miR-663 and miR-744 mediate inhibition of the proto-oncogene eEF1A2 expression that results in retardation of the MCF7 cancer cells proliferation. Antitumour effect of resveratrol may include stimulation of the miR-663 and miR-744 expression.
format Online
Article
Text
id pubmed-3681015
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-36810152014-06-11 Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744 Vislovukh, A Kratassiouk, G Porto, E Gralievska, N Beldiman, C Pinna, G El'skaya, A Harel-Bellan, A Negrutskii, B Groisman, I Br J Cancer Molecular Diagnostics BACKGROUND: Eukaryotic translation elongation factor 1A2 (eEF1A2) is a known proto-oncogene. We proposed that stimulation of the eEF1A2 expression in cancer tissues is caused by the loss of miRNA-mediated control. METHODS: Impact of miRNAs on eEF1A2 at the mRNA and protein levels was examined by qPCR and western blot, respectively. Dual-luciferase assay was applied to examine the influence of miRNAs on 3′-UTR of EEF1A2. To detect miRNA-binding sites, mutations into the 3′-UTR of EEF1A2 mRNA were introduced by the overlap extension PCR. RESULTS: miR-663 and miR-744 inhibited the expression of luciferase gene attached to the 3′-UTR of EEF1A2 up to 20% and 50%, respectively. In MCF7 cells, overexpression of miR-663 and miR-744 reduced the EEF1A2 mRNA level by 30% and 50%. Analogous effects were also observed at the eEF1A2 protein level. In resveratrol-treated MCF7 cells the upregulation of mir-663 and mir-744 was accompanied by downregulation of EEF1A2 mRNA. Both miRNAs were able to inhibit the proliferation of MCF7 cells. CONCLUSION: miR-663 and miR-744 mediate inhibition of the proto-oncogene eEF1A2 expression that results in retardation of the MCF7 cancer cells proliferation. Antitumour effect of resveratrol may include stimulation of the miR-663 and miR-744 expression. Nature Publishing Group 2013-06-11 2013-05-21 /pmc/articles/PMC3681015/ /pubmed/23695020 http://dx.doi.org/10.1038/bjc.2013.243 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Vislovukh, A
Kratassiouk, G
Porto, E
Gralievska, N
Beldiman, C
Pinna, G
El'skaya, A
Harel-Bellan, A
Negrutskii, B
Groisman, I
Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title_full Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title_fullStr Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title_full_unstemmed Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title_short Proto-oncogenic isoform A2 of eukaryotic translation elongation factor eEF1 is a target of miR-663 and miR-744
title_sort proto-oncogenic isoform a2 of eukaryotic translation elongation factor eef1 is a target of mir-663 and mir-744
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681015/
https://www.ncbi.nlm.nih.gov/pubmed/23695020
http://dx.doi.org/10.1038/bjc.2013.243
work_keys_str_mv AT vislovukha protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT kratassioukg protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT portoe protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT gralievskan protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT beldimanc protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT pinnag protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT elskayaa protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT harelbellana protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT negrutskiib protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744
AT groismani protooncogenicisoforma2ofeukaryotictranslationelongationfactoreef1isatargetofmir663andmir744